Medical Educational Resource
A Closer Look at Edasalonexent - A Potential New Treatment Option in Phase 3 Development for DMD
This program is sponsored by Catabasis. This program is not sponsored, endorsed, or accredited by MDA.
In this webinar, Edasalonexent, an oral NF-κB inhibitor, is being evaluated in the global Phase 3 PolarisDMD Trial as a potential foundational therapy for all ambulatory boys affected by Duchenne muscular dystrophy, regardless of underlying mutation.